Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Launched by ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY · Jun 18, 2019
Trial Information
Current as of June 28, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how genetic testing can help doctors choose the best treatments for patients with solid tumors that have spread to the brain. Researchers are particularly interested in specific genetic mutations, such as NTRK, ROS1, and KRAS G12C, which could affect how well certain medications work to stop the growth of these tumors. By identifying these mutations, doctors hope to tailor treatments to each patient's needs, using targeted therapies that block the growth of cancer cells.
To be eligible for this trial, patients must have confirmed brain metastases from any solid tumor and sufficient tissue available for testing. They should also be able to undergo MRI scans and have measurable brain lesions. Participants can expect to receive targeted treatments based on their genetic profile, while also being monitored closely for any side effects. It's important to note that patients who are pregnant or nursing cannot participate, and there are specific health criteria to ensure safety during the trial. If you or a loved one is considering joining, discussing eligibility and any concerns with your healthcare provider is a great first step.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • PRE-REGISTRATION ELIGIBILITY CRITERIA (ALL PATIENTS) • Tissue available for biomarker testing (any brain metastasis tissue and extracranial site from any prior resection or biopsy).
- • REGISTRATION ELIGIBILITY CRITERIA (ALL PATIENTS)
- • Participants must have histologically confirmed parenchymal metastatic disease to the brain from any solid tumor. Note: this includes patients that have controlled extracranial disease with progressive intracranial metastasis, as well as patients that have progressive intracranial and extracranial disease.
- * New or progressive brain metastases are defined as any one of the following:
- • Untreated measurable lesions in patients who have received surgery and/or stereotactic radiosurgery (SRS) to one or more other lesions.
- • Progressive measurable lesions after radiation, surgery, or prior systemic therapy
- • Residual or progressive lesions after surgery if asymptomatic.
- • Patients who have had prior whole-brain radiotherapy (WBRT) and/or SRS and then whose lesions have progressed by BM-RANO criteria or there are new lesions, are eligible. Lesions treated with SRS may be eligible if there is unequivocal evidence of progression. For patients with NTRK or ROS1 mutations, entrectinib may be used for newly diagnosed brain metastases. Similarly, for patients with KRAS G12C mutations, MRTX849 may be used for newly diagnosed brain metastases.
- • Patients who have not previously been treated with cranial radiation (e.g. WBRT or SRS) are eligible, but such patients must be asymptomatic or neurologically stable from their CNS metastases.
- • Measurable CNS disease (=\> 10 mm).
- • Ability to obtain magnetic resonance imaging (MRI)s with contrast
- • No surgery within 2 weeks prior to or after registration.
- • No chemotherapy within 14 days prior to registration (Note: for abemaciclib arm, a 21-day chemotherapy washout is required).
- • For melanoma, patients must have progressed after prior immune checkpoint blockade or for BRAF positive melanoma, BRAF/MEK inhibitors.
- • For lung cancer, EGFR mutant patients must have failed EGFR therapies
- • For HER2-positive breast cancer patients (regardless of ER/PR status), patients must have received at least one prior HER-2 directed therapy in the metastatic setting.
- • For triple negative breast cancer (TNBC), patients must have received at least one chemotherapy in the metastatic setting.
- • For estrogen receptor (ER) and/or progesterone receptor (PR)+ HER2-negative breast cancer, patients must have received at least one endocrine therapy in the metastatic setting.
- • Patients who have received prior treatment with any of the targeted treatments on this study are not eligible for that specific treatment arm(s), but could be eligible for other arms (e.g., a patient who has had prior treatment with abemaciclib would not be eligible for the abemaciclib arm, but could be eligible for another arm).
- • Presence of clinically actionable alteration in NTRK, ROS1, KRAS G12C or CDK pathway or PI3K pathway in both a brain metastasis and extracranial site per central review.
- • Not pregnant and not nursing, because this study involves investigational agents whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative pregnancy test done =\< 14 days prior to registration is required (Note: for abemaciclib arm, pregnancy test is required =\< 7 days prior to registration).
- • No known current diffuse leptomeningeal involvement for the CDK, PI3K and NTRK arms (diffuse defined as leptomeningeal involvement throughout the CNS axis).Patients with focal leptomeningeal disease, with or without documented positive CSF cytology, are eligible.
- • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- • Adequate organ function.
- • Absolute neutrophil count (ANC) \>= 1,500/mm\^3.
- • Platelet count \>= 100,000/mm\^3.
- • Total bilirubin =\< 1.5 x upper limit of normal (ULN) except in patients with Gilbert's disease. Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.
- • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN).
- • Creatinine =\< 1.5 mg/dL OR calculated (Calc.) creatinine clearance \> 45 mL/min except for patients in the adagrasib (MRTX849) (KRAS G12C) arm. For this arm, patients must have creatinine clearance ≥60 mL/min or glomerular filtration rate ≥60 mL/min/1.73m2 calculated using a validated prediction equation (e.g., Cockcroft-Gault, MDRD, or 24-hour urine CrCl).
- • No uncontrolled medical comorbidities per investigator discretion (e.g. interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea)
- • Radiation to symptomatic non-target sites within neural axis is allowed prior to registration without washout (provided there is at least one untreated target lesion for measurement on study and radiation is completed prior to registration).
- • Concurrent systemic corticosteroids are allowed if stable dose of dexamethasone for 7 days prior to registration. Baseline doses and changes in steroid dosing will be captured.
- • No concurrent administration of anticancer therapies (except for endocrine therapy or continuation of hormonal therapy or trastuzumab in breast cancer patients for the PI3K and CDK inhibitor arms). . No chemotherapy, targeted therapy or immunotherapy within 14 days prior to entering the study (Note: For abemaciclib arm, a 21-day chemotherapy washout is required).
- • Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug 14 days or 5 or more half-lives prior to registration on the study.
- • Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment.
- • ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR PAXALISIB ARM
- • Urine protein to creatinine (UPC) ratio \< 1 or urine protein =\< 1.
- • Recent acute myocardial infarction in the last 6 months or current angina pectoris are excluded. Patients with symptomatic bradycardia should have an electrocardiogram at baseline. If QT interval \> 470 msec, the patient is excluded.
- • Patients with uncontrolled type I or II diabetes mellitus should be excluded. Uncontrolled diabetes is defined as glycosylated hemoglobin (HbA1c) \> 9% in addition to fasting glucose \> 140 mg/dL on at least 2 occasions within 14 days prior to registration.
- • ADDITIONAL REGISTRATION ELIGIBILITY CRITERION FOR ENTRECTINIB ARM
- • • Concurrent use of H2 receptor antagonists, receptor antagonists, proton pump inhibitors (PPIs), and/or antacids are prohibited.
- • ADDITIONAL REGISTRATION ELIGIBILITY CRITERION FOR ABEMACICLIB ARM
- • Hemoglobin \>= g/dL. Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.
- • Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to registration. A washout period of at least 21 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy).
- • Patients who received adjuvant radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and registration.
- • Breast cancer patients who have received ribociclib or palbociclib are eligible as long as there is documentation of CDK4/6 pathway alteration on a biopsy or resection at the point of progression post-ribociclib or palbociclib.
- • For females of childbearing potential: A female of childbearing potential, must have a negative serum pregnancy test within 7 days prior to registration and agree to use a highly effective contraception method during the treatment period and for 3 weeks following the last dose of abemaciclib. Contraceptive methods may include an intrauterine device \[IUD\] or barrier method. If condoms are used as a barrier method, a spermicidal agent should be added as a double barrier protection. Cases of pregnancy that occur during maternal exposures to abemaciclib should be reported. If a patient or spouse/partner is determined to be pregnant following abemaciclib initiation, she must discontinue treatment immediately. Data on fetal outcome and breast-feeding are to be collected for regulatory reporting and drug safety evaluation.
- • Patients with active bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\] are excluded. Screening is not required for enrollment.
- • Patients with personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest, are excluded.
- • ADDITIONAL REGISTRATION ELIGIBILITY CRITERION FOR ADAGRASIB (MRTX849) ARM
- • Hemoglobin ≥9.0 g/dL. Note: Transfusions will be allowed to achieve this provided the patient has not received more than 2 units of red blood cells in the prior 4 weeks.
- • Any of the following cardiovascular abnormalities within 6 months of study entry are excluded: symptomatic or uncontrolled atrial fibrillation, unstable angina pectoris or myocardial infarction, CHF ≥ NYHA Class 3, stroke or transient ischemic attack.
- • Ongoing need for medication known to cause prolonged QTc interval or that are substrates of CYP3A4 with narrow therapeutic index that cannot be switched to alternative treatment prior to study entry is excluded.
- • Prolonged QTc interval \>480 milliseconds or family history or medical history of Long QT syndrome is excluded.•
- * Known human immunodeficiency virus (HIV) infection or acute or chronic hepatitis B or C infection is excluded. Screening is not required for enrollment. Note that the following are permitted:
- • Patients treated for hepatitis C (HCV) with no detectable viral load;
- • Patients treated for HIV with no detectable viral load for at least 1 month prior to randomization while on a stable regimen of agents that are not strong inhibitors of CYP3A4; and
- • Patients with hepatitis B (HBV) receiving prophylaxis against reactivation of hepatitis B (either \[HBsAg-positive with normal ALT and HBV DNA \<2,000 IU/mL or \<10,000 copies/mL\] or \[HBsAg-negative and anti-HBc positive\]).
- • History of intestinal disease or major gastric surgery likely to alter absorption of study treatment or inability to swallow oral medications is excluded.
- • Recovery from the adverse effects of prior therapy to baseline or Grade 1 (any grade alopecia and Grade ≤2 peripheral neuropathy are eligible).
- • For females of childbearing potential. It is not known whether MRTX849 presents a risk to the embryo or the fetus; however, based on the mechanism of action (KRAS G12C inhibition), effects on the reproductive system are not unexpected. MRTX849 is contraindicated in women who are pregnant or lactating. Women of childbearing potential and men receiving MRTX849 who are sexually active must employ an effective method of contraception throughout their period of treatment and for 6 months after their last treatment with MRTX849.
About Alliance For Clinical Trials In Oncology
The Alliance for Clinical Trials in Oncology is a prominent cooperative group dedicated to conducting high-quality, innovative clinical research aimed at improving cancer treatment and patient outcomes. Comprising a diverse network of institutions and investigators, the Alliance focuses on developing and implementing clinical trials that evaluate new therapies, treatment combinations, and prevention strategies across various cancer types. By fostering collaboration among oncologists, researchers, and healthcare professionals, the Alliance aims to accelerate the translation of scientific discoveries into effective clinical practices, ultimately enhancing the standard of care for cancer patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
New Haven, Connecticut, United States
Lebanon, New Hampshire, United States
Durham, North Carolina, United States
Cleveland, Ohio, United States
Milwaukee, Wisconsin, United States
Saint Louis, Missouri, United States
Flint, Michigan, United States
Philadelphia, Pennsylvania, United States
Denver, Colorado, United States
Flint, Michigan, United States
Kalamazoo, Michigan, United States
Burnsville, Minnesota, United States
Edina, Minnesota, United States
Waconia, Minnesota, United States
Boston, Massachusetts, United States
New Orleans, Louisiana, United States
Detroit, Michigan, United States
Anchorage, Alaska, United States
Oklahoma City, Oklahoma, United States
Des Moines, Iowa, United States
Great Falls, Montana, United States
Saint Paul, Minnesota, United States
Ann Arbor, Michigan, United States
Kalamazoo, Michigan, United States
Traverse City, Michigan, United States
Jackson, Mississippi, United States
Bozeman, Montana, United States
Kalispell, Montana, United States
Delaware, Ohio, United States
Sheridan, Wyoming, United States
Chicago, Illinois, United States
Cincinnati, Ohio, United States
Houston, Texas, United States
Dallas, Texas, United States
Oakland, California, United States
Mount Vernon, Illinois, United States
Coon Rapids, Minnesota, United States
Urbana, Illinois, United States
Carroll, Iowa, United States
Ann Arbor, Michigan, United States
Minneapolis, Minnesota, United States
Saint Paul, Minnesota, United States
Shakopee, Minnesota, United States
Willmar, Minnesota, United States
Torrance, California, United States
Council Bluffs, Iowa, United States
Dayton, Ohio, United States
Lawrence, Kansas, United States
Saint Joseph, Missouri, United States
Bethlehem, Pennsylvania, United States
Longmont, Colorado, United States
San Diego, California, United States
Fairfax, Virginia, United States
Downers Grove, Illinois, United States
Cincinnati, Ohio, United States
Portland, Oregon, United States
Hazel Crest, Illinois, United States
Summit, New Jersey, United States
Boston, Massachusetts, United States
Minneapolis, Minnesota, United States
Rochester, New York, United States
Philadelphia, Pennsylvania, United States
Salt Lake City, Utah, United States
Scottsdale, Arizona, United States
Orange, California, United States
Jacksonville, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
New Orleans, Louisiana, United States
Southfield, Michigan, United States
Saint Cloud, Minnesota, United States
Columbia, Missouri, United States
Kearney, Nebraska, United States
New York, New York, United States
New York, New York, United States
Syracuse, New York, United States
Chapel Hill, North Carolina, United States
Columbus, Ohio, United States
Pittsburgh, Pennsylvania, United States
Burlington, Vermont, United States
Aurora, Illinois, United States
Lexington, Kentucky, United States
Neptune, New Jersey, United States
Charlotte, North Carolina, United States
Columbus, Ohio, United States
Allentown, Pennsylvania, United States
Centralia, Washington, United States
Federal Way, Washington, United States
Lakewood, Washington, United States
Wyoming, Michigan, United States
Oakland, California, United States
Martinez, California, United States
Coos Bay, Oregon, United States
Pueblo, Colorado, United States
New Orleans, Louisiana, United States
Fridley, Minnesota, United States
Robbinsdale, Minnesota, United States
Saint Louis Park, Minnesota, United States
Saint Louis, Missouri, United States
Omaha, Nebraska, United States
Berlin, Vermont, United States
Omaha, Nebraska, United States
Glens Falls, New York, United States
Bethlehem, Pennsylvania, United States
Milwaukee, Wisconsin, United States
Fort Lauderdale, Florida, United States
Grand Rapids, Michigan, United States
Oak Lawn, Illinois, United States
Miami, Florida, United States
Park Ridge, Illinois, United States
Albuquerque, New Mexico, United States
Dallas, Texas, United States
Detroit, Michigan, United States
Rochester, Minnesota, United States
Saint Louis, Missouri, United States
Morristown, New Jersey, United States
Portland, Oregon, United States
Missoula, Montana, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Des Moines, Iowa, United States
Des Moines, Iowa, United States
Jackson, Michigan, United States
Lansing, Michigan, United States
Warren, Michigan, United States
Lincoln, Nebraska, United States
Papillion, Nebraska, United States
Anchorage, Alaska, United States
Omaha, Nebraska, United States
New York, New York, United States
Los Angeles, California, United States
Reed City, Michigan, United States
Des Moines, Iowa, United States
Adrian, Michigan, United States
Livonia, Michigan, United States
Monroe, Michigan, United States
Pontiac, Michigan, United States
Maplewood, Minnesota, United States
Maplewood, Minnesota, United States
Stillwater, Minnesota, United States
Great Falls, Montana, United States
Toledo, Ohio, United States
Kalamazoo, Michigan, United States
Bremerton, Washington, United States
Burbank, California, United States
Atlanta, Georgia, United States
Alton, Illinois, United States
Ames, Iowa, United States
Kansas City, Kansas, United States
New Orleans, Louisiana, United States
Worcester, Massachusetts, United States
Battle Creek, Michigan, United States
Grand Rapids, Michigan, United States
Grand Rapids, Michigan, United States
Muskegon, Michigan, United States
Saginaw, Michigan, United States
Saint Joseph, Michigan, United States
Woodbury, Minnesota, United States
Joplin, Missouri, United States
Springfield, Missouri, United States
Springfield, Missouri, United States
Billings, Montana, United States
Missoula, Montana, United States
Kinston, North Carolina, United States
Cincinnati, Ohio, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Mentor, Ohio, United States
Toledo, Ohio, United States
Troy, Ohio, United States
East Stroudsburg, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Burlington, Vermont, United States
Tacoma, Washington, United States
Vancouver, Washington, United States
Oconomowoc, Wisconsin, United States
Sheboygan, Wisconsin, United States
West Allis, Wisconsin, United States
Emeryville, California, United States
Colorado Springs, Colorado, United States
Lakewood, Colorado, United States
Columbus, Ohio, United States
Columbus, Ohio, United States
Bellingham, Washington, United States
Seattle, Washington, United States
Seattle, Washington, United States
Livonia, Michigan, United States
Mansfield, Ohio, United States
Bremerton, Washington, United States
Kennewick, Washington, United States
Sedro Woolley, Washington, United States
Clackamas, Oregon, United States
Newberg, Oregon, United States
Oshkosh, Wisconsin, United States
Littleton, Colorado, United States
New Ulm, Minnesota, United States
Albuquerque, New Mexico, United States
Boise, Idaho, United States
Hendersonville, North Carolina, United States
Saint Joseph, Michigan, United States
Elgin, Illinois, United States
Louisville, Kentucky, United States
Boca Raton, Florida, United States
Boise, Idaho, United States
Parker, Colorado, United States
La Jolla, California, United States
Warrenville, Illinois, United States
Shreveport, Louisiana, United States
Niles, Michigan, United States
Joplin, Missouri, United States
Lake Success, New York, United States
Walla Walla, Washington, United States
Grafton, Wisconsin, United States
Ft. Smith, Arkansas, United States
Grand Island, Nebraska, United States
Fort Smith, Arkansas, United States
Post Falls, Idaho, United States
Chicago, Illinois, United States
Geneva, Illinois, United States
Hays, Kansas, United States
Monroe, Louisiana, United States
Bolivar, Missouri, United States
Branson, Missouri, United States
Saint Louis, Missouri, United States
Concord, North Carolina, United States
Bend, Oregon, United States
Poulsbo, Washington, United States
Burlington, Wisconsin, United States
Germantown, Wisconsin, United States
Green Bay, Wisconsin, United States
Kenosha, Wisconsin, United States
Marinette, Wisconsin, United States
Milwaukee, Wisconsin, United States
Racine, Wisconsin, United States
Summit, Wisconsin, United States
Two Rivers, Wisconsin, United States
Wauwatosa, Wisconsin, United States
Houston, Texas, United States
Hot Springs, Arkansas, United States
Olathe, Kansas, United States
Saint Louis, Missouri, United States
Omaha, Nebraska, United States
Pennington, New Jersey, United States
Oklahoma City, Oklahoma, United States
Bryan, Texas, United States
Longview, Washington, United States
Dearborn, Michigan, United States
Emeryville, California, United States
Atlanta, Georgia, United States
Fruitland, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Twin Falls, Idaho, United States
West Des Moines, Iowa, United States
Overland Park, Kansas, United States
Kansas City, Missouri, United States
Lee's Summit, Missouri, United States
Rolla, Missouri, United States
Rolla, Missouri, United States
Albuquerque, New Mexico, United States
Elmira, New York, United States
Beachwood, Ohio, United States
Chardon, Ohio, United States
Middleburg Heights, Ohio, United States
Parma, Ohio, United States
Sandusky, Ohio, United States
Oregon City, Oregon, United States
Burien, Washington, United States
Edmonds, Washington, United States
Everett, Washington, United States
Issaquah, Washington, United States
Lacey, Washington, United States
New Richmond, Wisconsin, United States
Urbana, Illinois, United States
Columbus, Ohio, United States
Delaware, Ohio, United States
Brooklyn, New York, United States
Longmont, Colorado, United States
Saint Peters, Missouri, United States
Anchorage, Alaska, United States
New York, New York, United States
Fairfax, Virginia, United States
Great Falls, Montana, United States
Caldwell, Idaho, United States
Coeur D'alene, Idaho, United States
Emmett, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Sandpoint, Idaho, United States
Clive, Iowa, United States
West Des Moines, Iowa, United States
Garden City, Kansas, United States
Great Bend, Kansas, United States
Brighton, Michigan, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Canton, Michigan, United States
Caro, Michigan, United States
Chelsea, Michigan, United States
Chelsea, Michigan, United States
Clarkston, Michigan, United States
Clarkston, Michigan, United States
East China Township, Michigan, United States
Flint, Michigan, United States
Flint, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Livonia, Michigan, United States
Macomb, Michigan, United States
Macomb, Michigan, United States
Marlette, Michigan, United States
Pontiac, Michigan, United States
Pontiac, Michigan, United States
Pontiac, Michigan, United States
Rochester Hills, Michigan, United States
Saginaw, Michigan, United States
Sterling Heights, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
West Branch, Michigan, United States
Ypsilanti, Michigan, United States
Ypsilanti, Michigan, United States
Minneapolis, Minnesota, United States
Anaconda, Montana, United States
Centerville, Ohio, United States
Dublin, Ohio, United States
Marion, Ohio, United States
Wadsworth, Ohio, United States
West Chester, Ohio, United States
Baker City, Oregon, United States
Ontario, Oregon, United States
Cody, Wyoming, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Colorado Springs, Colorado, United States
Durango, Colorado, United States
Durango, Colorado, United States
Creston, Iowa, United States
Bardstown, Kentucky, United States
Corbin, Kentucky, United States
Lexington, Kentucky, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
Shepherdsville, Kentucky, United States
Cincinnati, Ohio, United States
Cincinnati, Ohio, United States
Aberdeen, Washington, United States
Enumclaw, Washington, United States
Seattle, Washington, United States
Shelton, Washington, United States
Tacoma, Washington, United States
Yelm, Washington, United States
Danville, Illinois, United States
Effingham, Illinois, United States
Mattoon, Illinois, United States
Yorkville, Illinois, United States
Louisville, Kentucky, United States
Brighton, Michigan, United States
Brownstown, Michigan, United States
Canton, Michigan, United States
Chelsea, Michigan, United States
Clinton Township, Michigan, United States
Novi, Michigan, United States
West Bloomfield, Michigan, United States
Ypsilanti, Michigan, United States
Maple Grove, Minnesota, United States
Wyoming, Minnesota, United States
Clackamas, Oregon, United States
Seattle, Washington, United States
Dublin, California, United States
Ames, Iowa, United States
Boone, Iowa, United States
Fort Dodge, Iowa, United States
Jefferson, Iowa, United States
Marshalltown, Iowa, United States
Walnut Creek, California, United States
Norton Shores, Michigan, United States
Novi, Michigan, United States
Monticello, Minnesota, United States
Creve Coeur, Missouri, United States
Saint Louis, Missouri, United States
Kenansville, North Carolina, United States
Richlands, North Carolina, United States
Ravenna, Ohio, United States
London, Kentucky, United States
Milwaukee, Wisconsin, United States
Mukwonago, Wisconsin, United States
Waukesha, Wisconsin, United States
Des Moines, Iowa, United States
Overland Park, Kansas, United States
Westwood, Kansas, United States
Westlake, Ohio, United States
Phoenix, Arizona, United States
Midlothian, Virginia, United States
Coral Gables, Florida, United States
Deerfield Beach, Florida, United States
Charlotte, North Carolina, United States
North Kansas City, Missouri, United States
Phoenix, Arizona, United States
San Luis Obispo, California, United States
Santa Maria, California, United States
Tawas City, Michigan, United States
Albuquerque, New Mexico, United States
Perrysburg, Ohio, United States
Seattle, Washington, United States
Fort Worth, Texas, United States
Dekalb, Illinois, United States
The Woodlands, Texas, United States
Arroyo Grande, California, United States
New Haven, Connecticut, United States
Springfield, Massachusetts, United States
Hazleton, Pennsylvania, United States
Ballwin, Missouri, United States
Washington, Missouri, United States
Fort Dodge, Iowa, United States
Redmond, Oregon, United States
Easton, Pennsylvania, United States
Lake Forest, Illinois, United States
Brighton, Michigan, United States
Burnsville, Minnesota, United States
Richmond, Virginia, United States
Bozeman, Montana, United States
Shelby, Michigan, United States
Cambridge, Minnesota, United States
Princeton, Minnesota, United States
Barrington, Illinois, United States
Crystal Lake, Illinois, United States
Shreveport, Louisiana, United States
Kalamazoo, Michigan, United States
Oneida, New York, United States
Dublin, Ohio, United States
Cudahy, Wisconsin, United States
New York, New York, United States
Humble, Texas, United States
Missoula, Montana, United States
Torrance, California, United States
Nampa, Idaho, United States
Alton, Illinois, United States
Grand Island, Nebraska, United States
Perrysburg, Ohio, United States
Quakertown, Pennsylvania, United States
Des Moines, Iowa, United States
Allentown, Pennsylvania, United States
Kalispell, Montana, United States
Lebanon, New Hampshire, United States
Wyoming, Michigan, United States
Grand Rapids, Michigan, United States
Muskegon, Michigan, United States
Nampa, Idaho, United States
Pontiac, Michigan, United States
Ann Arbor, Michigan, United States
Brighton, Michigan, United States
Chelsea, Michigan, United States
Dayton, Ohio, United States
Danville, Illinois, United States
Greenville, Ohio, United States
Boone, Iowa, United States
Fort Dodge, Iowa, United States
Jefferson, Iowa, United States
Marshalltown, Iowa, United States
Ames, Iowa, United States
Canton, Michigan, United States
Columbia, Missouri, United States
Verona, New York, United States
Ankeny, Iowa, United States
Niles, Michigan, United States
Reed City, Michigan, United States
Saint Joseph, Michigan, United States
Des Moines, Iowa, United States
Clive, Iowa, United States
Lansing, Michigan, United States
Grand Rapids, Michigan, United States
Hays, Kansas, United States
Saint Joseph, Michigan, United States
Pontiac, Michigan, United States
Kinston, North Carolina, United States
Silverdale, Washington, United States
Dayton, Ohio, United States
Grand Rapids, Michigan, United States
Sandpoint, Idaho, United States
Baker City, Oregon, United States
Ontario, Oregon, United States
Kenansville, North Carolina, United States
Richlands, North Carolina, United States
Saginaw, Michigan, United States
Tawas City, Michigan, United States
Shelby Township, Michigan, United States
Southfield, Michigan, United States
Novi, Michigan, United States
Detroit, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Macomb, Michigan, United States
Warren, Michigan, United States
Flint, Michigan, United States
Kalamazoo, Michigan, United States
Warren, Michigan, United States
East China Township, Michigan, United States
Macomb, Michigan, United States
Warren, Michigan, United States
Olathe, Kansas, United States
Grosse Pointe Woods, Michigan, United States
Rochester Hills, Michigan, United States
Mount Vernon, Illinois, United States
Ankeny, Iowa, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Des Moines, Iowa, United States
East China, Michigan, United States
Macomb Township, Michigan, United States
Macomb Township, Michigan, United States
Denver, Colorado, United States
Waukee, Iowa, United States
Rolla, Missouri, United States
Littleton, Colorado, United States
Parker, Colorado, United States
Patients applied
Trial Officials
Priscilla Brastianos, MD
Study Chair
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials